Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.32 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.31 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20133406 | 0.84 | NPY4R (0.34) | CNR1ITGB3ITGA2B | |
| SCHEMBL25477138 | 0.82 | KDM4E (0.34) | DPP4DPP8DPP9DPP7KISS1R | |
| SCHEMBL14509190 | 0.82 | KDM4E (0.34) | DPP4DPP8DPP9DPP7KISS1R | |
| SCHEMBL14402902 | 0.80 | KISS1R (0.39) | CNR1DPP7KISS1R | |
| SCHEMBL14509061 | 0.78 | KISS1R (0.38) | DPP7KISS1R | |
| SCHEMBL18233190 | 0.78 | KISS1R (0.38) | DPP7KISS1R | |
| SCHEMBL23287453 | 0.77 | MAOA (0.43) | CNR1DPP8DPP9DPP7MAOA | |
| SCHEMBL18233928 | 0.76 | BLM (0.46) | KISS1RITGB3ITGA2B | |
| SCHEMBL15030995 | 0.76 | BLM (0.46) | KISS1RITGB3ITGA2B | |
| SCHEMBL27405296 | 0.76 | ITGB3 (0.31) | ITGB3ITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10869863-B2 | Multi-arm polymeric targeting anti-cancer conjugate | BRIGHTGENE BIO-MEDICAL TECHNOLOGY CO., LTD. (CN) | 2020-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10869863-B2 | Multi-arm polymeric targeting anti-cancer conjugate | TOP2A, TOP1, ABCG2 | CNR1 4368/4885DPP4 4687/4885DPP8 4439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.